Home › Search
Search
439 results for "lecanemab".
Research summaries 393
Showing the best 200 of 393, 161–170, page 17 of 20. Filter these by subject, year and score in the research library →
-
Research summaries · alzhub.org/study/fatal-iatrogenic-cerebral-amyloid-related-encephalitis-in-a-patient-a81d7e99
… monoclonal antibody lecanemab where she was treated with the placebo, and subsequently in the open label extension study where she received lecanemab infusions every two weeks. After the third infusion, she suffered a seizure …
-
Baseline plasma C1q and C3 as potential biomarkers for lecanemab efficacy and ARIA risk in early Alzheimer's diseaseResearch summary
Research summaries · alzhub.org/study/baseline-plasma-c1q-and-c3-as-potential-biomarkers-for-lecanemab-42712875
… Alzheimer's disease initiating lecanemab. ARIA risk was evaluated in the safety cohort ( N = 62), and absolute amyloid reduction at week 26 was evaluated in the efficacy cohort with paired baseline and 26-week amyloid positron …
-
Clonal expansion of cytotoxic CD8⁺ T cells in lecanemab-associated ARIAResearch summary
Research summaries · alzhub.org/study/clonal-expansion-of-cytotoxic-cd8-t-cells-in-lecanemab-associated-aria-41617706
Amyloid-related imaging abnormalities (ARIA) are the principal safety concern limiting anti-amyloid therapies for Alzheimer's disease, yet their biology remains unclear. Here we show, through multi-omic profiling of peripheral …
-
Research summaries · alzhub.org/study/eligibility-rates-among-racially-and-ethnically-diverse-us-37830926
Objective Many factors contribute to inadequate diversity in Alzheimer disease (AD) clinical trials. We evaluated eligibility rates among racial and ethnic groups at US sites in large global multisite trials in early AD. Methods …
-
Real-world experience with lecanemab therapy for Alzheimer’s disease in the Intermountain WestResearch summary
Research summaries · alzhub.org/study/real-world-experience-with-lecanemab-therapy-for-alzheimers-disease-b62fc105
INTRODUCTION Lecanemab is a monoclonal antibody targeting amyloid plaques that has been approved for the treatment of Alzheimer’s disease. Here, we report on the clinical history and outcomes of the first 70 patients at the …
-
APOE-guided lecanemab dosing dissociates ARIA-E from ARIA-H: The K-ROAD studyResearch summary
Research summaries · alzhub.org/study/apoe-guided-lecanemab-dosing-dissociates-aria-e-from-aria-h-the-k-42642841
ARIA-E incidence was 2.0% in non-carriers and 6.2% in εε4/εε4 homozygotes (εε4/εε4-versus-non-carrier OR 3.25, versus 8.49 in Clarity AD and 8.32 in Japan post-marketing surveillance). Any ARIA-H was independently predicted by …
-
Research summaries · alzhub.org/study/clinically-important-benefits-and-harms-of-monoclonal-antibodies-38253509
… including those for lecanemab, aducanumab, and donanemab, exceeded the MCID. Harms included significantly increased risks of amyloid-related imaging abnormalities (ARIA)-edema (relative risk [RR] = 10.29; number needed to harm …
-
Research summaries · alzhub.org/study/comparison-of-the-efficacy-of-updated-drugs-for-the-treatment-on-the-39550061
… 95 % CI -5.08, 0.35), Lecanemab (MD -2.00, 95 % CI -5.25, 1.26), Donanemab (MD -1.45, 95 % CI -4.70, 1.81), Masupirdine (MD -0.83, 95 % CI -3.49, 1.84) were more effective than placebo in improving ADAS-cog. In terms of CDR-SB, …
-
Heterogeneity in plasma p-tau217 response and its association with cognitive trajectories under lecanemab treatmentResearch summary
Research summaries · alzhub.org/study/heterogeneity-in-plasma-p-tau217-response-and-its-association-with-42535277
Plasma p-tau217 levels decreased significantly from 3 months, with the greatest decline between 3 and 6 months, followed by a plateau. Two distinct trajectory groups were identified. Patients in the greater reduction group showed …
-
Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical CenterResearch summary
Research summaries · alzhub.org/study/initial-experience-with-lecanemab-and-lessons-learned-in-71-patients-39559868
Results The mean age was 72 years (49-90 years), and 44 (62%) patients were female. Results The mean age was 72 years (49-90 years), and 44 (62%) patients were female. The journal of prevention of Alzheimer's disease 2024 …
How this search works
There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.
One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.
31503 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-13. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.